Patent Document ID: 9928345
Application ID: 14589793
Patent Flag: 1

Claim One:
1. A method of evaluating a subject's risk of developing type 2 diabetes within 3 years and/or having pancreatic beta cell impairment and/or dysfunction, comprising: performing Nuclear Magnetic Resonance on a biosample from the subject to measure the concentration of a defined high density lipoprotein particle (HDL-P) subpopulation and the concentration of GlycA, programmatically calculating a short term diabetes risk factor (SDRF) score of the subject using a defined mathematical model, wherein the defined mathematical model includes i) the concentration measurement of the defined high density lipoprotein particle (HDL-P) subpopulation, ii) the concentration measurement of GlycA, and iii) an interaction parameter of the concentration measurements of the defined HDL-P subpopulation and GlycA, and wherein i)-iii) are mathematically combined with respective defined coefficients, and determining the subject is at risk of converting to type 2 diabetes mellitus within 3 years and/or is at risk of beta cell dysfunction when the SDRF score is at-a third tertile value or greater of the SDRF values of a study population.